Search
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigational[L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency, … On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA.
Categories: Drugs for Urinary Frequency and IncontinenceTuroctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalAs such, turoctocog alfa pegol is a valuable expansion to the drug therapies available for treating hemophilia A as it ultimately provides a less burdensome and more convenient dosing regimen for patients … This modification to the general turoctocog alfa rFVIII structure makes N8-GP an extended half-life factor VIII molecule for factor VIII replacement therapy in patients with factor VIII deficiency, or
Ustekinumab
go.drugbank.com/drugs/DB05679ApprovedInvestigationalactive psoriatic arthritis, alone or in combination with [methotrexate]. … In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.
Categories: Biologics for psoriasis treatmentProducts: Stelara Solution for Injection in Pre-Filled Syringe 90 mg/1 mL, STELARA 90MG/1ML SOLUTION FOR INJECTION IN PREFILLED SYRINGEVinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalWhile these patients have a median survival of approximately 4 months and a poor prognosis [L1396], there is currently no standard therapy in patients with advanced urothelial carcinoma [A32626]. … Vinflunine ditartrate is an active ingredient in the EMA-authorised product Javlor for intravenous infusion.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: Javlor Concentrate for Solution for Infusion 25 mg/mLBulevirtide
go.drugbank.com/drugs/DB15248ApprovedInvestigational[Peginterferon Alfa-2a]) in Patients With CHD. … [A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseVamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … option in patients for whom corticosteroid adverse effects are intolerable or otherwise unacceptable.
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, PlainSelexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalPAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. … Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
Technetium Tc-99m succimer
go.drugbank.com/drugs/DB09436Approved[L40558] The use of technetium Tc-99m succimer for the detection of kidney cortical defects was first approved by the FDA on February 23, 2022, under the market name NephroScan.[L40573] … function in patients with renal parenchymal disorders.
Categories: Compounds used in a research, industrial, or household settingCoenzyme M
go.drugbank.com/drugs/DB09110ApprovedInvestigationalCoenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]
Categories: Compounds used in a research, industrial, or household setting, Detoxifying Agents for Antineoplastic TreatmentProducts: Mesna for Injection, CONCENTRATE SOLUTION FOR INJECTION 400MG/4MLOfatumumab
go.drugbank.com/drugs/DB06650ApprovedInvestigational[L12771] It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate … has a higher affinity towards CD20.
Products: KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML, Bonspri 20mg/0.4mL Solution for Injection in Pre-filled syringe